US Patent Issued to Genentech on Sept. 8 for "Methods of treating lung cancer with a PD-1 axis binding antagonist, a platinum agent, and a topoisomerase II inhibitor" (American, Swiss Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,728,162, issued on Sept. 8, was assigned to Genentech Inc. (South San Francisco, Calif.).

"Methods of treating lung cancer with a PD-1 axis binding antagonist, a platinum agent, and a topoisomerase II inhibitor" was invented by Ariel Lopez-Chavez (South San Francisco, Calif.) and Daniel Antonius Waterkamp (Riehen, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., a...